The investigation began in 2023 when Mass Eye and Ear neuro-ophthalmologists noticed that three patients in their practice ...

After an alarming new study came out suggesting a link between semaglutide, the active ingredient in Ozempic and Wegovy, and a condition that can cause blindness, some experts are calling foul.

Novo Nordisk’s massively successful GLP-1 analog semaglutide, the active ingredient in the popular diabetes and obesity meds ...

Prescriptions with semaglutide (Wegovy, Ozempic, Novo Nordisk) are FDA approved to treat obesity and type 2 diabetes, ...

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic ...

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.

A new observational study reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy ...

In an observational retrospective study, researchers found that patients with type 2 diabetes or obesity who were taking ...

Being prescribed semaglutide for diabetes or weight management is associated with an increased risk, up to seven times, of ...

Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for ...

A study links semaglutide (the ingredient in Ozempic) with an increased risk for a rare eye disease, but that's not the full ...